Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation¹, in vitro stimulation, in vitro and in vivo blocking^1-4 of ligand binding, and as ELISA capture antibody⁵. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The Ultra LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 106327).

1. Walunas TL, et al. 1994. Immunity 1:405. (Block, IP)
2. Cilio CM, et al. 1998. J. Exp. Med. 188:1239. (Block)
3. Issazadeh S, et al. 1999. J. Immunol. 162:761. (Block)
4. McCoy K, et al. 1997. J. Exp. Med. 186:183. (Block)
5. Hsu HC, et al. 2007. J. Immunol. 178:5357. (ELISA Capture)
6. Sugita S, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:5783. PubMed

1. Schmitt E, et al. 2013. J Immunol. 191:5640. PubMed
2. Zhang P, et al. 2017. Int J Biol Macromol. 10.1016/j.ijbiomac.2017.06.023. PubMed
3. Lu SX, et al. 2021. Cell. . PubMed
4. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
5. Gubser C, et al. 2016. Sci Rep. 6: 25758. PubMed
6. Wong HS, et al. 2021. Cell. . PubMed
7. Sidwell T, et al. 2020. Nat Commun. 0.633333333. PubMed
8. Emmerson A, et al. 2018. J Clin Invest. 128:3088. PubMed
9. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
10. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
11. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
12. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
13. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
14. Katagiri T, et al. 2019. Mucosal Immunol. 12:p1104. PubMed
15. Severance AL, et al. 2022. iScience. 25:104400. PubMed
16. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
17. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
18. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
19. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
20. Long L, et al. 2021. Nature. 600:308. PubMed

Activated T cells and B cells

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Allison JP, et al. 1995. Science 270:932.
3. Waterhouse P, et al. 1995. Science 270:985.
4. Linsley PS, et al. 1991. J. Exp. Med. 174:561.